Combinations involving checkpoint therapies are starting to be used as the standard of care in certain metastatic cancer types, such as Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) with chemotherapy in advanced squamous non-small cell lung cancer, according to data and analytics company GlobalData.
Among the six approved checkpoint inhibitors - Keytruda, Bristol-Myers Squibb’s (NYSE: BMY) Opdivo (nivolumab) and Yervoy (ipilimumab), AstraZeneca’s (LSE: AZN) Imfinzi (durvalumab), Roche’s (ROG: SIX) Tecentriq (atezolizumab), and Merck KGaA (MRK: DE)/Pfizer’s (NYSE: PFE) Bavencio (avelumab) - the majority of ongoing Phase I to Phase III clinical trials involve a combination regimen.
Price barrier?
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze